- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00580450
Thymosin Alfa 1 in Recipients of Allogeneic Hematopoietic Transplantation for Hematological Malignancies
Phase I/II Clinical Trial on Thymosin Alfa 1 of Allogeneic Hematopoietic Transplantation
The purpose of this trial is to determine safety and efficacy of 16 weeks treatment with thymosin alpha 1 given at 1.6 mg dose once daily by subcutaneous injection in adult patients with hematological undergone allogenic bone marrow transplantation and CMV positive.
The efficacy will be explored assessing the ability of thymosin alpha1 to prevent the infection complications.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is an open label, monocenter, explorative study . A total of 9 patients will be included in the study in three sequential cohort of 3 patients each. Patients will enter into the study after meeting the inclusion and exclusion criteria and signing the Informed Consent Form.
The first three patients will be treated for 16 weeks starting 40 days after transplantation; if all three patients will complete the treatment period without any serious treatment related adverse event then the recruitment of second cohort of patients will be opened and patients treated starting from 20 days after transplantation. The same procedure will be applied for the third cohort of patients starting treatment from day of transplantation.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Andrae Velardi, MD, Prof.
- Phone Number: +39 075 578 3151
- Email: velardi@unipg.it
Study Locations
-
-
-
Perugia, Italy, 06122
- Hematology Section, University of Perugia
-
Contact:
- Massimo F Martelli, Prof
- Phone Number: +39 075 578 4170
- Email: ematol@unipg.it
-
Contact:
- Franco Aversa, Prof
- Phone Number: +39 075 578 4179
- Email: aversa@unipg.it
-
Sub-Investigator:
- Katia Perruccio, MD, PhD
-
Sub-Investigator:
- Luigina Romani, Prof
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Signed written informed consent.
- Age > 18 or < 55.
Patients with AML, ALL, or other haematological malignancies with an indication to transplant with or without a matched donor undergoing allogenic haploidentical hematopoietic transplantation (see Appendix 2) in any of the following categories:
Patients in first complete remission (CR) at high risk of relapse because of unfavourable cytogenetics, such as:
- t (9;22)
- 11q23 translocation
- complex karyotype
- t (8;12)/ETV6-AML
- t (6;9)/DEK-CAN
- t (11;14)(q15,q11)
- Trisomy 13
- FLT-3/ITD
Or other adverse prognostic factors, such as:
- Secondary leukemia
- CR after second line treatment
- High blast count
- Biphenotypic leukemia
- Patients in 2nd or 3rd CR or in chemoresistant relapse
- Recipient CMV positive as measured by pp65 antigenemia and PCR
- Adequate cardiac function: Asymptomatic of if symptomatic then left ventricular ejection fraction at rest be >45% and must improve with exercise,
- Adequate hepatic function: <2 x GOT and GPT and <2.0 mg total serum bilirubin unless liver is involved in disease,
- Adequate renal function: Serum creatinine within normal range or if serum creatinine outside normal range then creatinine clearance >50 ml/min,
- Adequate Pulmonary function: Diffusion capacity >50% of predicted (corrected for hemoglobin)
- Normal TSH or evidence of proper thyroid hormone replacement.
- For women of childbearing potential participating in the study, abstinence from sexual intercourses or use of a reliable form of effective contraception during the treatment period. These may include, but are not limited to, birth control pills, IUDs, condoms, diaphragms, implants, surgical sterilization, or being in a post-menopausal state.
- Negative pregnancy test prior to first study medication dose.
Exclusion Criteria:
- Evidence of active hepatitis (B and/or C) or cirrhosis
- HIV positive
- Presence of any other active, uncontrolled bacterial, viral or fungal infection
- Neurological or psychiatric dysfunctions which would impair compliance with the medical regimens and/or transplantation toleration
- Concomitant or prior history of malignancy other than surgically cured in situ carcinoma of the cervix.
- Pregnancy as documented by a urine pregnancy test or lactation.
- Any indication that the patient would not comply with the conditions of the study protocol.
- Previous treatment with thymosin alpha 1.
- Simultaneous participation in another investigational drug study or participation in any clinical trial involving investigational drugs within 3 months before study entry.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
|
1.6 mg sc once a day for 16 weeks
|
No Intervention: 2
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Efficacy in terms of improvement of immunological reconstitution, infectious mortality; safety as prevention of GvHD.
Time Frame: 3 years
|
3 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Andrea Velardi, Prof, Hematology Section, University of Perugia
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- (ST 1472)
- ST 1472 06/01/27
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hematological Malignancies
-
Tel-Aviv Sourasky Medical CenterMeir Medical Center; Max Planck Institute for Infection BiologyUnknownPediatric Solid Malignancies | Pediatric Hematological MalignanciesIsrael
-
Baylor College of MedicineCenter for Cell and Gene Therapy, Baylor College of MedicineCompletedMyeloid Hematological MalignanciesUnited States
-
Centre Hospitalier Universitaire de BesanconTerminatedHematological Malignancies BFrance
-
AdaptimmuneTerminatedSolid and Hematological MalignanciesUnited States, Canada
-
Senti BiosciencesNot yet recruitingAML/MDS | CD33 Expressing Hematological Malignancies | FLT3 Expressing Hematological Malignancies
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingRelapsed/Refractory Hematological MalignanciesChina
-
AdaptimmuneRecruitingSolid and Hematological MalignanciesUnited States, Spain, Canada, United Kingdom
-
Kite, A Gilead CompanyEnrolling by invitationSolid and Hematological MalignanciesUnited States, Netherlands, Japan, Australia, France, Israel, Germany, Canada, United Kingdom
-
AstraZenecaParexelCompletedSolid and Hematological MalignanciesGermany
-
CASI Pharmaceuticals, Inc.CompletedRelapsed or Refractory Hematological MalignanciesCanada
Clinical Trials on Thymosin alpha 1
-
sigma-tau i.f.r. S.p.A.CompletedMalignant MelanomaFrance, Germany, Hungary, Italy, Poland, Portugal, Spain, Switzerland
-
Weiqin LiJiangsu Province Hospital of Traditional Chinese Medicine; The First Affiliated... and other collaboratorsCompletedPancreatitis, Acute NecrotizingChina
-
Sun Yat-sen UniversitySciClone PharmaceuticalsCompleted
-
Sun Yat-sen UniversityCompleted
-
Shanghai Jiao Tong University School of MedicineUnknown2019 Novel Coronavirus InfectionChina
-
Sun Yat-sen UniversityCompleted
-
William B. Ershler, MDDavita Clinical Research; Clinical Research Consultants, LLCActive, not recruitingCOVID-19United States
-
SciClone PharmaceuticalsCompletedCarcinoma, HepatocellularUnited States
-
Sun Yat-sen UniversityCompletedNon-small Cell Lung CancerChina
-
Rhode Island HospitalTerminated